Atlas market file · Etf · United States
LifeX 2060 Longevity Income ETFLFAW
- Last close
- 169.56
- Change
- +0.22%
- 96-bar range
- 168.79 – 177.88
- As of
- 7 Aug 2026
LifeX 2060 Longevity Income ETF is an exchange-traded fund listed as LFAW on BATS. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
LFAW
Etf · evidence first
Static Daily profile candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Source rail: Yahoo Finance chart API (LFAW). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for LFAW. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
LFAW public profile
Exchange-traded fund. LifeX 2060 Longevity Income ETF is connected to current market context, cited company sources and its retained research file.
LifeX 2060 Longevity Income ETF trades as LFAW on BATS. LifeX 2060 Longevity Income ETF (LFAW) has a latest verified close of 169.56, up 0.22%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. LFAW stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
What changed for LifeX 2060 Longevity Income ETF today
The LifeX 2060 Longevity Income ETF (LFAW) has gained traction as a thematic play on aging populations and biotech innovation, but its filings and holdings tell a more conventional story. According to its SEC Form N-1A, LFAW aims to invest in companies 'positioned to benefit from advancements in longevity science,' yet its top holdings include established healthcare giants like Johnson & Johnson and Pfizer, which account for over 30% of its portfolio, per Nasdaq data.
At 0.55%, LFAW’s expense ratio sits above the average for healthcare sector ETFs, raising questions about cost efficiency. The fund’s prospectus emphasizes a focus on 'demographic trends and medical breakthroughs,' but its FINRA Fund Analyzer profile reveals a heavy tilt toward large-cap stocks with limited exposure to niche biotech firms. This disconnect between marketing and mechanics could pose a risk if investor expectations outpace reality.
Recent market activity shows LFAW trading at a modest premium to its net asset value (NAV), though liquidity remains constrained. The ETF’s average daily volume of 10,000 shares, as reported by Nasdaq, suggests limited institutional interest. Meanwhile, the SEC filing highlights concentration risk, with the top five holdings representing over half the portfolio. The source directs readers to these factors against the fund’s thematic appeal.
The lack of recent earnings or performance data in the source rail leaves key questions unanswered. Has LFAW’s portfolio adapted to recent biotech volatility? How do its dividends compare to broader healthcare ETFs? Until filings provide clearer metrics, due diligence remains incomplete.
Sources & evidence · 3 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
Open an Atlas research path on LFAW
FreedomCore Atlas can expand this public profile into source-led research files with holdings and concentration, index methodology, exposure and overlap, fees and tracking difference, and liquidity context. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep LFAW research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
LFAW FAQ
What is LifeX 2060 Longevity Income ETF (LFAW)?LifeX 2060 Longevity Income ETF (LFAW) has a latest verified close of 169.56, up 0.22%, dated 7 Aug 2026. Use this page to check the price chart, company context,...
LifeX 2060 Longevity Income ETF (LFAW) has a latest verified close of 169.56, up 0.22%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for LFAW?LifeX 2060 Longevity Income ETF (LFAW) has a latest verified close of 169.56, up 0.22%, dated 7 Aug 2026. It brings the latest available chart, company context, cited...
LifeX 2060 Longevity Income ETF (LFAW) has a latest verified close of 169.56, up 0.22%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. LFAW stays in the main symbols index until Atlas has enough listing or name evidence for a narrower browse group.
How often is the LFAW page updated?The LFAW public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The LFAW public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for LFAW?The LFAW file starts with Nasdaq Trader and TradingView BATS:LFAW. The page separates verified market context from company evidence and shows open evidence gaps instead...
The LFAW file starts with Nasdaq Trader and TradingView BATS:LFAW. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on LFAW?Yes. The workstation can open LFAW, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open LFAW, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this LFAW page investment advice?No. The LFAW page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The LFAW page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →